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retreatment regimens, which allows continuous or paused therapeutic schemes.
This study aims to perform cost-effectiveness and cost-utility analyses of biologic
alternatives for moderate to severe psoriasis in Venezuela, from a public payer=s
perspective.METHODS: A decision-tree model simulates psoriasis evolution after
treatment with etanercept continuous (50mg twice a week for 12 weeks, followed
by 25mg twice a week) or paused (12-week treatment cycle and 12-week interrup-
tion), adalimumab (80mg at first week, followed by 40mg in the second week, then
40mg every 2 weeks), infliximab (5 mg/kg at weeks 0, 2 and 6, then every 8 weeks)
or ustekinumab (45mg in weeks 0 and 4, then 45mg every 12 weeks) and their
associated costs in a 96-week time horizon. Therapy continuation or switch was
evaluated atweek 24. Effectivenessmeasureswere PASI 75 success rate and quality
adjusted life years (QALY) gained. Costs included biologicals, medical follow-up
and adverse events management, from Venezuela official databases (values repre-
sented 2010USD). Probabilistic sensitivity analyseswere performed throughMonte
Carlo simulation. A 5% discount rate was applied for costs and benefits. RESULTS:
Effectiveness resulted in [PASI 75, QALY]: etanercept [51.3%, 1.5360], adalimumab
[50.5%, 1.5339], infliximab [37.2%,1.5001] and ustekinumab [43.6%, 1.5164]. Treat-
ment costs [continuous, paused] were [16,741USD, 15,692USD], [17,846USD,
19,742USD], [35,685USD, 33,980USD] and [27,569USD, 26,922USD], respectively. Et-
anercept represented the least costly in all comparisons. Acceptability curves
showed etanercept in continuous and paused schemes as the most cost-effective
biologic. CONCLUSIONS: In this analysis, due to its lower costs and favorable ef-
fectiveness profile, etanercept showed to be cost-saving in both continuous and
paused treatment schemes regarding PASI 75 success rate and QALY’s gained.
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OBJECTIVES: Regarding biological drugs approved for psoriasis in Argentina, etan-
ercept effectiveness is not lost in retreatment regimens, which allows continuous
or paused therapeutic schemes. This study aims to perform cost-effectiveness and
cost-utility analyses of biologic alternatives for moderate to severe psoriasis in
Argentina, from a public payer’s perspective. METHODS: A decision-tree model
was used to simulate etanercept continuous (50mg twice a week for 12 weeks,
followed by 25mg twice a week) or paused (12-week cycle and 12-week interrup-
tion), adalimumab (80mg at first week, followed by 40mg in the second week, and
then 40mg every two weeks) or infliximab (5 mg/kg at weeks 0, 2 and 6 and then
every 8 weeks) in a 96-week time horizon. Therapy continuation or switch was
evaluated atweek 24. Effectivenessmeasureswere PASI 75 success rate and quality
adjusted life years (QALYs) gained. Costs included biologicals, medical follow-up
and adverse events management from Argentina official databases (values repre-
sented in 2010 USD). Probabilistic sensitivity analyses were performed through
Monte Carlo simulation. A 5% discount rate was applied for costs and benefits.
RESULTS: Effectiveness resulted in [PASI 75, QALY]: etanercept [51.3%, 1.5360],
adalimumab [50.5%, 1.5339] and infliximab [37.2%, 1.5001]. Treatment costs [con-
tinuous, paused] for etanercept, adalimumab and infliximab were [80,633USD,
60,056USD], [73,439USD, 74,362USD] and [112,274USD, 107,267USD], respectively. In
continuous scheme etanercept saved 31,641USD when compared to infliximab. In
paused scheme, etanercept represented the least costly treatment in all compari-
sons: 14,306USD and 47,211USD less than adalimumab and infliximab, respec-
tively. Acceptability curves showed etanercept paused as the most cost-effective
biologic. CONCLUSIONS: In this analysis, etanercept presented the greatest effec-
tiveness in continuous and paused therapeutic schemes. Due to its lower costs in
paused scheme scenario, etanercept showed to be cost-saving regarding PASI 75
success rate and QALY’s gained.
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OBJECTIVES: Biologic treatment after systemic drugs fail in psoriasis is indicated
for obtaining clinical response, but not yet available in the Brazilian public health
care system. Etanercept effectiveness is not lost in retreatment regimens, which
allows continuous or paused therapeutic schemes. This study aims to perform
cost-effectiveness and cost-utility analysis of biologic alternatives for moderate to
severe psoriasis in Brazil, from a public payer’s perspective.METHODS:A decision-
tree model simulates psoriasis evolution after treatment with etanercept paused
(50mg twice a week for 12 weeks, followed by 25mg twice a week; 12-week treat-
ment cycle and 12-week interruption), adalimumab (80mg at first week, followed
by 40mg in the second week, and then 40mg every two weeks), infliximab (5mg/kg
at weeks 0, 2 and 6 and then every 8 weeks) or ustekinumab (45mg in weeks 0 and
4, then 45mg every 12 weeks) and their associated costs in a 96-week time horizon.
Therapy continuation or switch was evaluated at week 24. Effectiveness measures
were PASI 75 success rate and quality adjusted life years (QALY) gained. Costs
included biologicals,medical follow-up and adverse eventsmanagement, collected
from Brazil public official databases (values represented 2010 USD). Probabilistic
sensitivity analyses were performed troughMonte Carlo simulation. A 5% discount
ratewas applied for costs and benefits.RESULTS: Effectiveness resulted in [PASI 75,
QALY] etanercept [51.3%, 1.5360], adalimumab [50.5%, 1.5339], infliximab [37.2%,
1.5001] and ustekinumab [43.6%, 1.5164]. Treatment costs were 28,051USD,
35,001USD, 35,987USD and 40,183, respectively, and etanercept represented the
least costly in all comparisons: 6,951USD, 7,937USD and 12,132USD less than ada-
limumab, infliximab and ustekinumab, respectively. Acceptability curves showed
etanercept paused as themost cost-effective biologic. CONCLUSIONS: In this anal-
ysis, etanercept in paused therapeutic scheme presented the greatest effective-
ness. Due to its lower costs, etanercept showed to be cost-saving regarding PASI 75
success rate and QALY’s gained.
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OBJECTIVES: Biologic treatment in psoriasis is indicated for obtaining clinical re-
sponse after systemic drugs fail. Among those approved in Colombia, etanercept
effectiveness is not lost in retreatment regimens, which allows continuous or
paused therapeutic schemes. This study aims to perform cost-effectiveness and
cost-utility analysis of biologic alternatives for moderate to severe psoriasis in
Colombia, from a public payer’s perspective. METHODS: A decision tree-model
simulates psoriasis evolution after treatment with etanercept continuous (50mg
twice a week for 12 weeks, followed by 25mg twice a week) or paused (12-week
treatment cycle and 12-week interruption), adalimumab (80mg at first week, fol-
lowed by 40mg in the second week, then 40mg every two weeks), infliximab
(5mg/kg at weeks 0, 2 and 6, then every 8 weeks) or ustekinumab (45mg in weeks 0
and 4, then 45mg every 12 weeks) and their associated costs in a 96-week time
horizon. Therapy continuation or switch was evaluated at week 24. Effectiveness
measures were PASI 75 success rate and quality adjusted life years (QALY) gained.
Costs included biologicals, medical follow-up and adverse events management,
collected from Colombia official databases (values represented 2010 USD). Proba-
bilistic sensitivity analyses were performed trough Monte Carlo simulation. A 5%
discount rate was applied for costs and benefits. RESULTS: Effectiveness resulted
in [PASI 75, QALY] etanercept [51.3%, 1.5360], adalimumab [50.5%, 1.5339], inflix-
imab [37.2%, 1.5001] and ustekinumab [43.6%, 1.5164]. Treatment costs [continu-
ous, paused] were [45,683USD, 35,420USD], [44,467USD, 45,123USD], [60,359USD,
58,335USD] and [42,818USD, 43,306USD], respectively. In continuous scheme etan-
ercept saved 14,678USD when compared to infliximab. In paused scheme, etaner-
cept represented the least costly in all comparisons. Acceptability curves showed
etanercept paused as themost cost-effective biologic. CONCLUSIONS: In this anal-
ysis, etanercept presented the greatest effectiveness in all therapeutic schemes.
Due to its lower costs in paused scenario, etanercept showed to be cost-saving
regarding PASI 75 success rate and QALY’s gained.
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OBJECTIVES: Age-related macular degeneration (AMD) is the primary cause of vi-
sion loss among older Americans and results in significant cost and reduced quality
of life. This study reviewed the methodology and results of published cost-utility
analyses (CUA) in AMD treatments. METHODS: We identified AMD-related CUAs
published from 2000 through 2010 using the Tufts Medical Center Cost-Effective-
ness Analysis Registry (www.cearegisty.org), which contains detailed information
onmore than 2,600 CUAs. In addition to the standard auditing process,we recorded
model structure, cost and effectiveness inputs, and assumptions employed in the
models. RESULTS:We identified 26 AMD-related CUAs containing 55 standardized
incremental cost-effectiveness ratios (ICERs, expressed as $US2010 per QALY) and
82 utility weights. The most common type of intervention was pharmaceuticals
(pegaptanib, ranibizumab, bevacizumab, vitamin therapy and/or antioxidants),
followed by medical procedures (laser photocoagulation, photodynamic therapy
with verteporfin). Approximately 55% of the reported ICERs were either dominant
(less expensive and more effective) or below $50,000 per QALY gained. Most of the
CUAs used Markov modeling over a lifetime horizon and estimated ICERs from
payer’s perspective. Vision acuity was typically modeled with static rather than
dynamic states. Most CUAs extrapolated effectiveness data beyond the timeframe
of clinical trials by using the “last-observation-carried forward” approach. Most
studies considered binocular AMD, but only considered the treatment, monitoring,
and utilityweight of the better-seeing eye. Key drivers of ICERs included the clinical
efficacy of treatment, utility weights, time horizon, and discount rate.
CONCLUSIONS: CUAs in AMD therapies suggest good value in many cases, but
great variations exist in the cost-effectiveness of AMD interventions, as well as
methods and assumptions employed in the CUA models. Few studies modeled
both the better-seeing and worse-seeing eyes among AMD patients. Future re-
search is needed to better understand the cost-effectiveness of treating bilateral
AMD based on longer-term data.
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